Businesses in the industry are always concentrating on tactics like joint ventures and the The market for Cancer Diagnostics Market is expected to increase rapidly worldwide. Although Cancer Diagnostics Market have made great strides, one of the main obstacles to their clinical application is the laborious process of converting them into practical clinical assays. This market is expected to rise due to reasons like rising healthcare costs, more funding for research and development, the growing use of biomarkers for diagnostic purposes, and an increase in Cancer Diagnostics Market research.
The scale of the Market was verified, and the sizes of several other dependent submarkets were estimated, using both top-down and bottom-up methods. Secondary research was used to identify the market’s major participants, and primary and secondary research was used to calculate their market revenues. While primary research involved in-depth interviews with important opinion leaders like CEOs, directors, and marketing executives, secondary research involved examining the annual and financial reports of major market competitors. Primary sources were used to verify the segment % splits, shares, and breakdowns that were calculated from secondary sources. This report presents the combined data together with in-depth inputs and analysis from us.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Cancer Diagnostics Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering market details, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
Cancer Diagnostics Market based on Biopsy and Cytology Tests:
- Tumor Biomarkers
- Other Diagnostic Types
Cancer Diagnostics Market based on Application:
- Breast Cancer
- Lung Cancer
- Cervical Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Other Applications
Cancer Diagnostics Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The market for cancer diagnostics has been divided into categories based on type, including biomarker testing, imaging testing, in vitro diagnostic testing, biopsy, and other categories. Due to factors like the growing use of in-vitro diagnostics, the in vitro diagnostic testing category led the market growth in 2021 and is anticipated to expand at the fastest rate during the forecast period, 2024–2032. The major players in the sector are introducing a growing number of in vitro diagnostics products, which is driving the market’s expansion.
Based on application, the cancer diagnostics market is divided into segments for lung, breast, colorectal, melanoma, prostate, liver, and other cancers. In 2021, the breast cancer sector held the largest share of the market revenue. It is anticipated that during the forecast period, 2024–2032, this segment will increase at a quicker rate. This expansion can be attributed to the increasing incidence of breast cancer. One kind of cancer that starts in the breast cells and progresses gradually is called breast cancer. The market for breast cancer is growing as a result of more people getting mammograms.
The market for cancer diagnostics is divided into diagnostic centers, hospitals and clinics, research institutes, and others based on end-users and market data. Hospitals and clinics held the most market share in 2021 and are anticipated to increase at the fastest rate between 2024 and 2032. The market is expanding as a consequence of efforts, increased accessibility to healthcare services, and greater awareness of personalized medicine.
The report offers market insights for cancer diagnostics by geographic region, covering North America, Europe, Asia-Pacific, and the Rest of the World. The market for cancer diagnostics in North America was valued at USD 8.4 billion in 2021 and is projected to grow at a 42.80% CAGR over the course of the study. Large corporations that are taking more calculated risks are driving this sector. For example, Agilent acquired Resolution Bioscience Inc. in March 2021. The acquisition complements and expands the company’s capabilities in NGS-based cancer diagnostics and gives it access to state-of-the-art technology to address the growing demands of the precision medicine sector.
Market growth for cancer diagnostics in Asia-Pacific is anticipated to accelerate significantly between 2022 and 2030. as a result of calculated actions taken by large corporations, a notable rise in the number of cervical screening programs implemented to enhance awareness and screening, a rise in research and development, and technological advancements. In addition, the market for cancer diagnostics in China had the biggest market share, while the market in India was expanding at the quickest rate in the area.
Manufacturing locally to cut operational costs is one of the main business strategies used by manufacturers in the cancer diagnostics sector to serve customers and grow the industry. The field of cancer diagnosis has yielded some of the greatest medical advances in recent years. Major players in the market include GE Healthcare, QIAGEN N.V., Abbott Laboratories, Becton Dickinson and Company (BD), Biotheranostics, Agilent Technologies, Arquer Diagnostics Ltd., BioMark Diagnostics Inc., and Exact Sciences Corporation.
- This report illustrates the most vital attributes of the Cancer Diagnostics Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Cancer Diagnostics Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Cancer Diagnostics Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Cancer Diagnostics Market.
Methodology
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
List of Tables
TABLE 1. CANCER DIAGNOSTICS MARKET VALUE, BY BIOPSY AND CYTOLOGY TESTS, 2021-2030 (USD BILLION)
TABLE 2. CANCER DIAGNOSTICS MARKET VALUE FOR TUMOR BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. CANCER DIAGNOSTICS MARKET VALUE FOR OTHER DIAGNOSTIC TYPES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 5. CANCER DIAGNOSTICS MARKET VALUE FOR BREAST CANCER, 2021-2030 (USD BILLION)
TABLE 6. CANCER DIAGNOSTICS MARKET VALUE FOR LUNG CANCER, 2021-2030 (USD BILLION)
TABLE 7. CANCER DIAGNOSTICS MARKET VALUE FOR CERVICAL CANCER, 2021-2030 (USD BILLION)
TABLE 8. CANCER DIAGNOSTICS MARKET VALUE FOR KIDNEY CANCER, 2021-2030 (USD BILLION)
TABLE 9. CANCER DIAGNOSTICS MARKET VALUE FOR PANCREATIC CANCER, 2021-2030 (USD BILLION)
TABLE 10. CANCER DIAGNOSTICS MARKET VALUE FOR LIVER CANCER, 2021-2030 (USD BILLION)
TABLE 11. CANCER DIAGNOSTICS MARKET VALUE FOR OTHER APPLICATIONS, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 15. U.S CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 16. U.S CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 17. CANADA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 19. MEXICO CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 20. MEXICO CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. EUROPE CANCER DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 22. EUROPE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 23. EUROPE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 24. GERMANY CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 25. GERMANY CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 26. U.K CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 27. U.K CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 28. FRANCE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 29. FRANCE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 30. ITALY CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. ITALY CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 32. SPAIN CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 33. SPAIN CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 34. ROE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 35. ROE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. ASIA PACIFIC CANCER DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 37. ASIA PACIFIC CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 38. ASIA PACIFIC CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 39. CHINA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 40. CHINA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 41. INDIA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 42. INDIA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 43. JAPAN CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 44. JAPAN CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 45. REST OF APAC CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 46. REST OF APAC CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 47. LATIN AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. LATIN AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. BRAZIL CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. BRAZIL CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 51. ARGENTINA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 52. ARGENTINA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 53. MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 54. MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 55. SAUDI ARABIA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. SAUDI ARABIA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 57. UAE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 58. UAE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 59. REST OF MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 60. REST OF MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 61. EXACT SCIENCES CORPORATION: FINANCIALS
TABLE 62. EXACT SCIENCES CORPORATION: PRODUCTS & SERVICES
TABLE 63. EXACT SCIENCES CORPORATION: RECENT DEVELOPMENTS
TABLE 64. ARQUER DIAGNOSTICS LTD: FINANCIALS
TABLE 65. ARQUER DIAGNOSTICS LTD: PRODUCTS & SERVICES
TABLE 66. ARQUER DIAGNOSTICS LTD: RECENT DEVELOPMENTS
TABLE 67. BIOMARK DIAGNOSTICS INC.: FINANCIALS
TABLE 68. BIOMARK DIAGNOSTICS INC.: PRODUCTS & SERVICES
TABLE 69. BIOMARK DIAGNOSTICS INC.: RECENT DEVELOPMENTS
TABLE 70. BIOTHERANOSTICS: FINANCIALS
TABLE 71. BIOTHERANOSTICS: PRODUCTS & SERVICES
TABLE 72. BIOTHERANOSTICS: RECENT DEVELOPMENTS
TABLE 73. AGILENT TECHNOLOGIES: FINANCIALS
TABLE 74. AGILENT TECHNOLOGIES: PRODUCTS & SERVICES
TABLE 75. AGILENT TECHNOLOGIES: RECENT DEVELOPMENTS
TABLE 76. THERMO FISHER SCIENTIFIC: FINANCIALS
TABLE 77. THERMO FISHER SCIENTIFIC: PRODUCTS & SERVICES
TABLE 78. THERMO FISHER SCIENTIFIC: RECENT DEVELOPMENTS
TABLE 79. ILLUMINA: FINANCIALS
TABLE 80. ILLUMINA: PRODUCTS & SERVICES
TABLE 81. ILLUMINA: DEVELOPMENTS
TABLE 82. GE HEALTHCARE: FINANCIALS
TABLE 83. GE HEALTHCARE: PRODUCTS & SERVICES
TABLE 84. GE HEALTHCARE: RECENT DEVELOPMENTS
TABLE 85. QIAGEN N.V.: FINANCIALS
TABLE 86. QIAGEN N.V.: PRODUCTS & SERVICES
TABLE 87. QIAGEN N.V.: RECENT DEVELOPMENTS
TABLE 88. ABBOTT LABORATORIES: FINANCIALS
TABLE 89. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 90. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
